Cai Jing Wang·2025-10-31 03:13Core Viewpoint - China Resources Pharmaceutical announced the establishment of a 500 million yuan fund focused on investments in high-growth companies in synthetic biology, innovative drugs, and biotechnology sectors [1] Group 1: Fund Details - The fund will be established with China Resources Pharmaceutical (Shantou) as the general partner, and China Resources Double Crane (600062) and China Resources Pharmaceutical Investment as limited partners [1] - China Resources Pharmaceutical Group plans to invest 123 million yuan, accounting for approximately 24.6% of the total fund size [1] - Shenzhen China Resources Capital will act as the fund manager [1] Group 2: Strategic Goals - The establishment of the fund aligns with the group's strategic direction in synthetic biology, aiming to build an industrialization platform in Hohhot [1] - The fund is expected to enhance investment channels, promote innovation incubation, accelerate product technology collaboration, and secure commercialization rights for products [1] - Once established, the fund will be recorded as equity investment in the company's consolidated financial statements [1]